NC 100182

Drug Profile

NC 100182

Alternative Names: Helispin

Latest Information Update: 08 Sep 2006

Price : $50

At a glance

  • Originator GE Healthcare
  • Class Contrast media
  • Mechanism of Action Magnetic resonance imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Chronic obstructive pulmonary disease

Most Recent Events

  • 08 Sep 2006 Discontinued - Phase-II for Chronic obstructive pulmonary disease (diagnosis) in USA (Inhalation)
  • 16 Apr 2004 Amersham has merged with GE Medical Systems to form GE Healthcare
  • 15 Mar 2002 Phase-II clinical trials in Chronic obstructive pulmonary disease (diagnosis) in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top